Day: July 3, 2024

Long-term survival data from DESTINY-Breast03 trial

With a longer follow-up of 41 months, trastuzumab-deruxtecan continues to demonstrate superior efficacy over trastuzumab-emtansine in HER2+ metastatic breast cancer